Edition:
United States

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.27USD
23 Mar 2017
Change (% chg)

$0.03 (+2.42%)
Prev Close
$1.24
Open
$1.26
Day's High
$1.30
Day's Low
$1.24
Volume
630,105
Avg. Vol
1,246,376
52-wk High
$8.49
52-wk Low
$1.16

Latest Key Developments (Source: Significant Developments)

Novavax reports Q4 loss per share $0.21
Monday, 27 Feb 2017 04:10pm EST 

Novavax Inc : Novavax reports fourth quarter and year-end 2016 financial results . Q4 loss per share $0.21 . Q4 earnings per share view $-0.23 -- Thomson Reuters I/B/E/S .Q4 revenue $5.4 million versus I/B/E/S view $5.5 million.  Full Article

Novavax initiates Phase 2 safety and immunogenicity trial of RSV F vaccine in older adults
Thursday, 19 Jan 2017 04:05pm EST 

Novavax Inc : Novavax initiates Phase 2 safety and immunogenicity trial of the RSV F vaccine in older adults .Novavax Inc says top-line results are expected in Q3 of 2017.  Full Article

Novavax initiates phase 2 safety and immunogenicity trial of the RSV F vaccine in older adults
Thursday, 19 Jan 2017 04:05pm EST 

Novavax Inc : Novavax initiates phase 2 safety and immunogenicity trial of the RSV F vaccine in older adults .Top-Line results are expected in Q3 of 2017 for RSV F vaccine.  Full Article

Novavax Inc files for mixed shelf of upto $125 mln - SEC filing
Friday, 30 Dec 2016 05:29pm EST 

Novavax Inc :Novavax Inc - files for mixed shelf of upto $125 million - SEC filing.  Full Article

Novavax Q2 loss per share $0.29
Tuesday, 9 Aug 2016 04:05pm EDT 

Novavax Inc : Novavax reports second quarter 2016 financial results . Q2 earnings per share view $-0.25 -- Thomson Reuters I/B/E/S . Q2 revenue fell 82 percent to $2.5 million . Q2 loss per share $0.29 . Q2 revenue view $8 million -- Thomson Reuters I/B/E/S .Says research and development expenses increased 134% to $64.9 million in q2 of 2016, compared to $27.7 million for same period in 2015.  Full Article

FDA grants fast track designation to Novavax' RSV F vaccine
Wednesday, 25 May 2016 08:00am EDT 

Novavax Inc :U.S. FDA grants fast track designation to Novavax' RSV F vaccine for older adults.  Full Article

Novavax Announces Closing of $300 Million Offering of Convertible Senior Notes Due 2023
Friday, 29 Jan 2016 02:54pm EST 

Novavax, Inc:Says closing of its previously announced offering of $300 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023 (the Notes).Under the purchase agreement, the initial purchasers may exercise their option to purchase up to an additional $30 million aggregate principal amount of the Notes solely to cover over-allotments any time before February 24, 2016.Citigroup and J.P. Morgan acted as joint book-running managers of the offering. Piper Jaffray and Guggenheim Securities acted as Co-Lead Managers.Notes bear cash interest at a rate of 3.75%, payable on February 1 and August 1 of each year, beginning on August 1, 2016.The Notes are not redeemable prior to maturity and are convertible into shares of Novavax common stock.The initial conversion rate for the Notes is 146.8213 shares of Novavax' common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $6.81 per share of Novavax' common stock.The net proceeds of the offering were approximately $291 million, after deducting the initial purchasers' discounts and commissions, but prior to deducting estimated offering expenses.Novavax used approximately $34.7 million of the net proceeds from the offering to pay the cost of the previously announced capped call transactions.  Full Article

Novavax announces proposed offering of $200 mln of convertible senior notes due 2023
Monday, 25 Jan 2016 07:00am EST 

Novavax Inc:Announced that it intends to offer, subject to market and other conditions, $200 million aggregate principal amount of convertible senior unsecured notes that will mature on February 1, 2023.Intends to use the net proceeds from the offering for the advancement of its clinical-stage vaccine candidates.  Full Article

Novavax Inc Initiates pivotal phase 3 trial of RSV F vaccine in older adults
Monday, 9 Nov 2015 06:50am EST 

Novavax Inc:Says initiation of a Phase 3 clinical trial, known as Resolve(tm), of its respiratory syncytial virus F-protein nanoparticle vaccine candidate (RSV F Vaccine) in older adults.Primary efficacy objective of the Resolve trial is the prevention of moderate-severe RSV-associated lower respiratory tract disease, as defined by the presence of multiple lower respiratory tract symptoms.Top-line results expected in the second half of 2016.  Full Article

Novavax announces Positive Top-Line Data From RSV F Vaccine Phase 1 Clinical Trial in Pediatrics
Tuesday, 29 Sep 2015 04:02pm EDT 

Novavax:Positive top-line data from a Phase 1 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in healthy children.Says All RSV F Vaccine formulations and regimens were well-tolerated and highly immunogenic.  Full Article

More From Around the Web

BRIEF-Novavax reports Q4 loss per share $0.21

* Novavax reports fourth quarter and year-end 2016 financial results